How DYNLL1 and 53BP1 control DNA repair in BRCA1-related cancers
Project 1: Role of DYNLL1 in the 53BP1 Axis of HDR Regulation
This project looks at whether the protein DYNLL1 changes how cells repair broken DNA and how that affects BRCA1-related tumors' response to therapies.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11143723 on NIH RePORTER |
What this research studies
You can expect lab-based work that follows how DYNLL1 binds to 53BP1 and MRE11 to control the switch between homology-directed repair (HDR) and non-homologous end joining (NHEJ). Researchers will use cellular and molecular experiments, including modified cells and biochemical assays, to study DYNLL1 phosphorylation and its effects on DNA end resection. The team will test how loss or alteration of DYNLL1 or 53BP1 changes sensitivity to PARP inhibitors in BRCA1-deficient models. Results are meant to link these molecular changes to mechanisms that drive treatment resistance.
Who could benefit from this research
Good fit: Patients with BRCA1-mutated breast or ovarian cancers, especially those being treated with or who have stopped responding to PARP inhibitors, would be most relevant.
Not a fit: People without BRCA1-related tumors or those with cancers driven by unrelated mutations are less likely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this work could point to new tests or drug targets to predict or overcome PARP inhibitor resistance in BRCA1-mutant cancers.
How similar studies have performed: Previous studies show that altering 53BP1-pathway proteins can restore DNA resection and change PARP inhibitor response, but targeting DYNLL1 specifically is a newer, less-tested approach.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Chowdhury, Dipanjan — University of Texas Hlth Science Center
- Study coordinator: Chowdhury, Dipanjan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.